Experts highlight management nuances in patients with neuropathic pain, post–refractive surgery complications, or contact lens intolerance.
BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal” or the "Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved ...
BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved ...
Are you the owner of a spankin' new Nintendo Switch 2 console? Have you been holding off on a memory card upgrade until prices have dropped? If you answered "yes" to both questions, then you, my ...
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) received U.S. Food and Drug Administration approval for its cyclosporine ophthalmic emulsion 0.05%, a generic version of Allergan’s ...
Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback